|Bid||1,643.20 x 0|
|Ask||1,643.80 x 0|
|Day's Range||1,639.60 - 1,651.00|
|52 Week Range||1,408.80 - 1,767.00|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||18.50|
|Forward Dividend & Yield||0.76 (4.67%)|
|1y Target Est||N/A|
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
The settlement could be valued at up to $12 billion, they said, which would make it the largest such settlement in U.S. pharmaceutical history. The following are some of the largest previous U.S. legal settlements involving the pharmaceutical industry. * Merck & Co $4.85 billion, 2007 - Three years after it pulled its widely used arthritis pain drug Vioxx from the market over safety concerns and following several product liability trials, Merck agreed to pay nearly $5 billion to settle most of the 60,000 lawsuits alleging that Vioxx caused heart attacks and strokes.
Shares of generic pharmaceutical companies rallied Friday after Perrigo announced its acquisition of GlaxoSmithKline's heartburn treatment, a medicine known as Prevacid 24-hour.
Aiming to use so-called "natural killer" cells to rev up the immune system against cancer, Nkarta Therapeutics Inc. raised $114 million from a lineup of biotech and crossover investors that hints at an IPO. The South San Francisco company, headed by biotech industry leader Paul Hastings, plans to enter clinical trials with two types of engineered natural killer cells, part of the body's innate immune system that forms a frontline defense against foreign invaders.
Jim Cramer said on CNBC's "Mad Money Lightning Round" that he likes GlaxoSmithKline plc (NYSE: GSK ). He thinks it's terrific and the CEO is doing a great job. Cramer would sell Centurylink Inc ...
Jim Cramer weighed in on a number of stocks during the Lightning Round of Mad Money Tuesday night. One name was GlaxoSmithKline plc : "I think they're terrific and they're doing a great job." Let's check out the charts of this global pharmaceutical firm. In the daily bar chart of GSK, below, we can see that prices have been making higher lows from December to the end of May to the middle of August.
GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business. Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion last year and an agreement in February to pay up to 3.7 billion euros ($4.09 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.
ViiV, in which Pfizer and Shionogi have small stakes, is working on two-drug combinations and will use the lower drug burden in comparison with three-drug cocktails such as Gilead's Biktarvy as its main selling point to patients and physicians. It is banking on longer-term studies to yield hard evidence of fewer side effects over time.
GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences. GSK's two-drug injection was as effective as a monthly dose of the same regimen in maintaining viral suppression at 48 weeks in a late-stage study, said ViiV Healthcare, GSK's HIV unit. ViiV, in which Pfizer and Shionogi have small stakes, is working on two-drug combinations and will use the lower drug burden in comparison with three-drug cocktails such as Gilead's Biktarvy as its main selling point to patients and physicians.
With the change of leadership for GSK's pharmaceutical business, the Triangle won't necessarily be losing its GSK leader.